×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
INNV – innovage holding corp. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
INNV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
08:14 am
innv
InnovAge Holding Corp. (NASDAQ: INNV) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $5.00 price target on the stock.
Medium
Report
InnovAge Holding Corp. (NASDAQ: INNV) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $5.00 price target on the stock.
12/13
07:03 am
innv
InnovAge offers all-inclusive care center that nurtures passions for seniors in Philadelphia [CBS News]
Medium
Report
InnovAge offers all-inclusive care center that nurtures passions for seniors in Philadelphia [CBS News]
12/12
08:17 am
innv
InnovAge Celebrates 35 Years of Transforming Senior Care [Yahoo! Finance]
Medium
Report
InnovAge Celebrates 35 Years of Transforming Senior Care [Yahoo! Finance]
12/12
08:00 am
innv
InnovAge Celebrates 35 Years of Transforming Senior Care
Medium
Report
InnovAge Celebrates 35 Years of Transforming Senior Care
11/6
02:33 am
innv
InnovAge Holding Corp (INNV) Q1 2025 Earnings Call Highlights: Revenue Surge and Operational ... [Yahoo! Finance]
High
Report
InnovAge Holding Corp (INNV) Q1 2025 Earnings Call Highlights: Revenue Surge and Operational ... [Yahoo! Finance]
11/5
04:05 pm
innv
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2024
Medium
Report
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2024
11/4
08:27 am
innv
InnovAge names Michael Scarbrough as COO Nov. 04, 2024 8:25 AM ET By: Sinchita Mitra , SA News Editor [Seeking Alpha]
Low
Report
InnovAge names Michael Scarbrough as COO Nov. 04, 2024 8:25 AM ET By: Sinchita Mitra , SA News Editor [Seeking Alpha]
11/4
08:00 am
innv
InnovAge Appoints Michael Scarbrough as New President and Chief Operating Officer and Maria Lozzano as President, Pharmacy Services
Medium
Report
InnovAge Appoints Michael Scarbrough as New President and Chief Operating Officer and Maria Lozzano as President, Pharmacy Services
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/6
08:04 am
innv
Form 8-K InnovAge Holding Corp. For: Dec 05
Low
Report
Form 8-K InnovAge Holding Corp. For: Dec 05
12/3
04:04 pm
innv
Form 4 InnovAge Holding Corp. For: Dec 01 Filed by: BLAIR PATRICK T
Low
Report
Form 4 InnovAge Holding Corp. For: Dec 01 Filed by: BLAIR PATRICK T
11/13
07:45 pm
innv
Form SC 13G/A InnovAge Holding Corp. Filed by: TCO GROUP HOLDINGS, L.P.
Medium
Report
Form SC 13G/A InnovAge Holding Corp. Filed by: TCO GROUP HOLDINGS, L.P.
11/8
04:04 pm
innv
Form 4 InnovAge Holding Corp. For: Nov 06 Filed by: DAMATO NICOLE
Low
Report
Form 4 InnovAge Holding Corp. For: Nov 06 Filed by: DAMATO NICOLE
11/5
05:08 pm
innv
Form 10-Q InnovAge Holding Corp. For: Sep 30
High
Report
Form 10-Q InnovAge Holding Corp. For: Sep 30
11/5
04:07 pm
innv
Form 8-K InnovAge Holding Corp. For: Nov 05
Medium
Report
Form 8-K InnovAge Holding Corp. For: Nov 05
11/4
04:49 pm
innv
Form 3 InnovAge Holding Corp. For: Nov 04 Filed by: SCARBROUGH MICHAEL ANTHONY
Low
Report
Form 3 InnovAge Holding Corp. For: Nov 04 Filed by: SCARBROUGH MICHAEL ANTHONY
11/4
08:05 am
innv
Form 8-K InnovAge Holding Corp. For: Oct 30
Medium
Report
Form 8-K InnovAge Holding Corp. For: Oct 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/31
Form 8-K INNOVUS PHARMACEUTICALS, For: May 28
14.5%
1/15 Form SC 13G INNOVUS PHARMACEUTICALS, Filed by: LGH Investments, LLC 11.6%
8/9 Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019 11.6%
9/23 Form 425 INNOVUS PHARMACEUTICALS, Filed by: AYTU BIOSCIENCE, INC 8.4%
6/4 Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC) 7.3%
2/14 Form 8-K INNOVUS PHARMACEUTICALS, For: Feb 13 6.0%
6/19 Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada 5.6%
9/13 Form 425 INNOVUS PHARMACEUTICALS, Filed by: INNOVUS PHARMACEUTICALS, INC. 3.8%
5/8 Innovus Pharma Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women 3.4%
5/28 Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union 3.4%
1/15 Form SC 13G INNOVUS PHARMACEUTICALS, Filed by: LGH Investments, LLC 11.6%
8/9 Innovus Pharmaceuticals to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 13, 2019 11.6%
9/23 Form 425 INNOVUS PHARMACEUTICALS, Filed by: AYTU BIOSCIENCE, INC 8.4%
6/4 Innovus Pharma Expands its OTC Drug Pipeline with the Addition of OmepraCare™ (a Competitor of Prilosec® OTC) 7.3%
2/14 Form 8-K INNOVUS PHARMACEUTICALS, For: Feb 13 6.0%
6/19 Innovus Pharmaceuticals Announces Progress in Fulfilling the Regulatory and Manufacturing Steps to Receive Market Authorization for FlutiCare® in Canada 5.6%
9/13 Form 425 INNOVUS PHARMACEUTICALS, Filed by: INNOVUS PHARMACEUTICALS, INC. 3.8%
5/8 Innovus Pharma Announces a Second Partnered United States OTC ANDA for Minoxidil 5% Foam for Men and Women 3.4%
5/28 Following Its Recent Approval from Health Canada for the Relief of Neuropathy Pain, Innovus Pharma Announces Receipt of Notification to Commercialize Diabasens® in the European Union 3.4%
TOP News Decliners
5/15
Innovus Pharma Reports Quarterly Revenue for the First Quarter 2019 of $5.4 Million, a 18.0% Increase from Comparable Quarter in the Prior Year
-15.1%
8/13 Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter -10.1%
6/10 Form S-8 INNOVUS PHARMACEUTICALS, -8.1%
9/18 Form 3 INNOVUS PHARMACEUTICALS, For: Sep 13 Filed by: Armistice Capital Master Fund Ltd. -7.9%
9/17 Innovus Pharmaceuticals Inc (OTCMKTS: INNV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. -6.9%
11/15 Innovus Pharmaceuticals Inc (OTCMKTS: INNV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. -6.1%
5/6 Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million -5.7%
5/13 Innovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that Country -2.2%
7/22 Form 8-K INNOVUS PHARMACEUTICALS, For: Jul 22 -1.9%
6/6 Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union -1.5%
8/13 Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter -10.1%
6/10 Form S-8 INNOVUS PHARMACEUTICALS, -8.1%
9/18 Form 3 INNOVUS PHARMACEUTICALS, For: Sep 13 Filed by: Armistice Capital Master Fund Ltd. -7.9%
9/17 Innovus Pharmaceuticals Inc (OTCMKTS: INNV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. -6.9%
11/15 Innovus Pharmaceuticals Inc (OTCMKTS: INNV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock. -6.1%
5/6 Innovus Pharmaceuticals Reports Preliminary Q1 2019 Sales Revenue of Approximately $5.4 million -5.7%
5/13 Innovus Pharma’s Partner Lavasta Receives Approval from Algeria to Market and Sell Zestra® and Zestra Glide® in that Country -2.2%
7/22 Form 8-K INNOVUS PHARMACEUTICALS, For: Jul 22 -1.9%
6/6 Innovus Pharmaceuticals Receives Notification to Market and Sell CarvaNum® for Muscle Recovery in the European Union -1.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: